B Borroni1, C Agosti, G Bellelli, A Padovani. 1. Department of Neurology, University of Brescia, Center for Aging Brain and Dementia, Brescia, Italy. bborroni@inwind.it
Abstract
BACKGROUND AND PURPOSE: Frontotemporal dementia (FTD) is the second most common neurodegenerative dementia in the young age after Alzheimer disease. Recent improvement in diagnostic assessment suggests that it is more common than previously, although with a great heterogeneity in clinical presentation. The different clinical patterns related to age of disease onset in behavioural variant FTD (bvFTD) have been fairly studied. Aim of the study was to evaluate whether age at disease onset modulate the heterogeneity of either cognitive impairment or behavioural disturbances in patients affected by bvFTD. METHODS: One hundred and thirty-four patients with bvFTD entered the study. Age at onset and demographic characteristics were carefully recorded. Each patient underwent a wide neuropsychological and behavioural standardized assessment, as well as a brain SPECT perfusion imaging study. RESULTS: Behavioural variant FTD were subdivided into four groups according to the age at onset. The four quartile groups did not differ for demographic characteristics and family history for dementia. Global cognitive impairment as well as analysis of the different cognitive domains and behavioural patterns were comparable. CONCLUSIONS: These findings provide evidence that the clinical heterogeneity of bvFTD is not explained by age at disease onset. Further studies are needed.
BACKGROUND AND PURPOSE: Frontotemporal dementia (FTD) is the second most common neurodegenerative dementia in the young age after Alzheimer disease. Recent improvement in diagnostic assessment suggests that it is more common than previously, although with a great heterogeneity in clinical presentation. The different clinical patterns related to age of disease onset in behavioural variant FTD (bvFTD) have been fairly studied. Aim of the study was to evaluate whether age at disease onset modulate the heterogeneity of either cognitive impairment or behavioural disturbances in patients affected by bvFTD. METHODS: One hundred and thirty-four patients with bvFTD entered the study. Age at onset and demographic characteristics were carefully recorded. Each patient underwent a wide neuropsychological and behavioural standardized assessment, as well as a brain SPECT perfusion imaging study. RESULTS: Behavioural variant FTD were subdivided into four groups according to the age at onset. The four quartile groups did not differ for demographic characteristics and family history for dementia. Global cognitive impairment as well as analysis of the different cognitive domains and behavioural patterns were comparable. CONCLUSIONS: These findings provide evidence that the clinical heterogeneity of bvFTD is not explained by age at disease onset. Further studies are needed.
Authors: Martin N Rossor; Nick C Fox; Catherine J Mummery; Jonathan M Schott; Jason D Warren Journal: Lancet Neurol Date: 2010-08 Impact factor: 44.182
Authors: Jay L P Fieldhouse; Flora T Gossink; Thomas C Feenstra; Sterre C M de Boer; Afina W Lemstra; Niels D Prins; Femke Bouwman; Ted Koene; Hanneke F M Rhodius-Meester; Freek Gillissen; Charlotte E Teunissen; Wiesje M van der Flier; Philip Scheltens; Annemieke Dols; Everard G B Vijverberg; Yolande A L Pijnenburg Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: José Manuel Santacruz Escudero; Jonathan Beltrán; Álvaro Palacios; Claudia Marcela Chimbí; Diana Matallana; Pablo Reyes; Victor Perez-Sola; Hernando Santamaría-García Journal: Front Aging Neurosci Date: 2019-07-24 Impact factor: 5.750
Authors: Sang Won Seo; Marie-Pierre Thibodeau; David C Perry; Alice Hua; Manu Sidhu; Isabel Sible; Jose Norberto S Vargas; Stephanie E Gaus; Gil D Rabinovici; Katherine D Rankin; Adam L Boxer; Joel H Kramer; Howard J Rosen; Maria Luisa Gorno-Tempini; Lea T Grinberg; Eric J Huang; Stephen J DeArmond; John Q Trojanowski; Bruce L Miller; William W Seeley Journal: Neurology Date: 2018-02-16 Impact factor: 9.910